In 2019, Bobart et al. [10], reported the Mayo experience, showing that a positive test for anti-PLA2R serology in patients who presented with nephrotic syndrome, normal kidney function, and no evidence of another process to account for proteinuria was sufficient to make a diagnosis of primary MN without the need for a diagnostic kidney biopsy. The gene discussed is PLA2R1; the disease is nephrotic syndrome.